Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

• US 20060264465A1
• Filed: 05/03/2006
• Published: 11/23/2006
• Est. Priority Date: 01/16/2003
• Status: Active Grant

• Current Assignee: Acadia Pharmaceuticals Inc.
• Original Assignee: Acadia Pharmaceuticals Inc.
• Inventors: Davis, Robert E., Brann, Mark R., Weiner, David M.
• Granted Patent: US 7,732,462 B2
• Time in Patent Office: Days
• US Class Current: 514/317
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/194 having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• CPC Class Codes: A61K 31/4468 having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/20 Pills, tablets, discs, rods A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/06 Antimigraine agents
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: C07C 59/255 : Tartaric acid
• CPC Class Codes: C07D 211/58 : attached in position 4
• CPC Class Codes: C12Q 2600/106 : Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/156 : Polymorphic or mutational markers

Abstract

Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson'"'"'s Disease, related human neurodegenerative diseases, and psychosis.

Claims

1. A method of treating a condition that can be caused by dopaminergic therapy, the method comprising administering a therapeutically effective amount of a compound of Formula (I) to a subject suffering from said condition:

2. The method of claim 1, wherein the condition is one that can be caused by antagonizing a dopamine receptor.

3. The method of claim 1, wherein the condition is one that can be caused by antagonizing a dopamine D2 receptor.

4. The method of claim 1, wherein the condition is one that can be caused by administration of an antipsychotic agent.

5. The method of claim 1, wherein the condition is selected from the group consisting of dyskinesia, dystonia, myoclonus, tremor, and psychosis.

6. The method of claim 1, wherein administering the compound of Formula (I) comprises contacting a pituitary cell with the compound.

7. The method of claim 1, further comprising identifying the subject as having the condition.

8. A method of treating a condition that can be caused by administering an antipsychotic agent, the method comprising administering a therapeutically effective amount of a compound of Formula (I) to a subject suffering from said condition:

9. A method of improving a pathophysiology in a pituitary cell, the method comprising administering a compound of Formula (I) in an amount effective to improve the pathophysiology of the pituitary cell to a subject suffering from said pathophysiology:

10. The method of claim 9, wherein the pathophysiology is one that results in a condition in the subject that can be caused by administering an antipsychotic agent to the subject.

11. The method of claim 9, wherein the pathophysiology is one that results in a condition in the subject that can be caused by antagonism of a D2 doapmine receptor.

12. A method of improving a pathophysiology in a pituitary cell, the method comprising contacting the pituitary cell with a compound of Formula (I) in an amount effective to improve the pathophysiology of the pituitary cell:

13. The method of claim 12, wherein the pathophysiology is one that results in a condition in a subject that can be caused by administering an antipsychotic agent to the subject.

14. The method of claim 12, wherein the pathophysiology is one that results in a condition in a subject that can be caused by antagonism of a D2 doapmine receptor.

15. A method of inversely agonizing a 5-HT2A receptor in a pituitary cell, comprising contacting the pituitary cell with a compound of Formula (I) in an amount effective to inversely agonize the receptor:

16. The method of claim 15, wherein the amount is effective to treat a condition that can be caused by dopaminergic therapy.